Radiotherapy after Neoadjuvant Immunochemotherapy in Unresectable Stage III Non-Small Cell Lung Carcinoma: A Novel Therapeutic Approach?

Peizhu Wu , Chaozhuo Li , Zhonghui Wei , Xiangjiao Meng

Precision Radiation Oncology ›› 2025, Vol. 9 ›› Issue (2) : 143 -144.

PDF
Precision Radiation Oncology ›› 2025, Vol. 9 ›› Issue (2) : 143 -144. DOI: 10.1002/pro6.70012
PERSPECTIVE

Radiotherapy after Neoadjuvant Immunochemotherapy in Unresectable Stage III Non-Small Cell Lung Carcinoma: A Novel Therapeutic Approach?

Author information +
History +
PDF

Keywords

immunotherapy / non-small cell lung carcinoma / neoadjuvant therapy

Cite this article

Download citation ▾
Peizhu Wu, Chaozhuo Li, Zhonghui Wei, Xiangjiao Meng. Radiotherapy after Neoadjuvant Immunochemotherapy in Unresectable Stage III Non-Small Cell Lung Carcinoma: A Novel Therapeutic Approach?. Precision Radiation Oncology, 2025, 9(2): 143-144 DOI:10.1002/pro6.70012

登录浏览全文

4963

注册一个新账户 忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within
[1]

Zhou Q, Pan Y, Yang X, et al. Neoadjuvant SHR-1701 with or without chemotherapy in unresectable stage III non-small-cell lung cancer: A proof-of-concept, phase 2 trial. Cancer Cell. 2024; 42(7): 1258-1267.e2.
[2]

Bradley JD, Sugawara S, Lee KHH, et al. LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2. ESMO Open. 2024; 9(Suppl 3): 102986.
[3]

Ohri N, Jolly S, Cooper BT, et al. Selective Personalized RadioImmunotherapy for Locally Advanced Non-Small-Cell Lung Cancer Trial (SPRINT). J Clin Oncol. 2024; 42(5): 562-570.

RIGHTS & PERMISSIONS

2025 The Author(s). Precision Radiation Oncology published by John Wiley & Sons Australia, Ltd on behalf of Shandong Cancer Hospital & Institute.

AI Summary AI Mindmap
PDF

32

Accesses

0

Citation

Detail
Sections
Recommended

AI思维导图

/

〈 〉